PMID- 21415842
OWN - NLM
STAT- MEDLINE
DCOM- 20111013
LR  - 20220330
IS  - 1941-7225 (Electronic)
IS  - 0895-7061 (Print)
IS  - 0895-7061 (Linking)
VI  - 24
IP  - 7
DP  - 2011 Jul
TI  - Telmisartan provides better renal protection than valsartan in a rat model of 
      metabolic syndrome.
PG  - 816-21
LID - 10.1038/ajh.2011.34 [doi]
AB  - BACKGROUND: Angiotensin receptor blockers (ARB), telmisartan, and valsartan were 
      compared for renal protection in spontaneously hypertensive rats (SHR) fed high 
      fat diet. We hypothesized that in cardiometabolic syndrome, telmisartan an ARB 
      with peroxisome proliferators activated receptor-gamma (PPAR-gamma) activity will offer 
      better renal protection. METHODS: SHR were fed either normal (SHR-NF, 7% fat) or 
      high fat (SHR-HF, 36% fat) diet and treated with an ARB for 10 weeks. RESULTS: 
      Blood pressure was similar between SHR-NF (190 +/- 3 mm Hg) and SHR-HF (192 +/- 4 mm 
      Hg) at the end of the 10 week period. Telmisartan and valsartan decreased blood 
      pressure to similar extents in SHR-NF and SHR-HF groups. Body weight was 
      significantly higher in SHR-HF (368 +/- 5 g) compared to SHR-NF (328 +/- 7 g). 
      Telmisartan but not valsartan significantly reduced the body weight gain in 
      SHR-HF. Telmisartan was also more effective than valsartan in improving glycemic 
      and lipid status in SHR-HF. Monocyte chemoattractant protein-1 (MCP-1), an 
      inflammatory marker, was higher in SHR-HF (24 +/- 2 ng/d) compared to SHR-NF (14 +/- 
      5 ng/d). Telmisartan reduced MCP-1 excretion in both SHR-HF and SHR-NF to a 
      greater extent than valsartan. An indicator of renal injury, urinary albumin 
      excretion increased to 85 +/- 8 mg/d in SHR-HF compared to 54 +/- 9 mg/d in SHR-NF. 
      Telmisartan (23 +/- 5 mg/d) was more effective than valsartan (45 +/- 3 mg/d) in 
      lowering urinary albumin excretion in SHR-HF. Moreover, telmisartan reduced 
      glomerular damage to a greater extent than valsartan in the SHR-HF. CONCLUSIONS: 
      Collectively, our data demonstrate that telmisartan was more effective than 
      valsartan in reducing body weight gain, renal inflammation, and renal injury in a 
      rat model of cardiometabolic syndrome.
FAU - Khan, Abdul Hye
AU  - Khan AH
AD  - Department of Pharmacology & Toxicology and Cardiovascular Research Center, 
      Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
FAU - Imig, John D
AU  - Imig JD
LA  - eng
GR  - P01 DK038226/DK/NIDDK NIH HHS/United States
GR  - R01 HL059699/HL/NHLBI NIH HHS/United States
GR  - HL-59699/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20110317
PL  - United States
TA  - Am J Hypertens
JT  - American journal of hypertension
JID - 8803676
RN  - 0 (Angiotensin II Type 2 Receptor Blockers)
RN  - 0 (Benzimidazoles)
RN  - 0 (Benzoates)
RN  - 0 (Dietary Fats)
RN  - 0 (PPAR gamma)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - HG18B9YRS7 (Valine)
RN  - U5SYW473RQ (Telmisartan)
SB  - IM
CIN - Am J Hypertens. 2011 Jul;24(7):739. PMID: 21681185
MH  - Angiotensin II Type 2 Receptor Blockers/pharmacology/therapeutic use
MH  - Animals
MH  - Benzimidazoles/pharmacology/*therapeutic use
MH  - Benzoates/pharmacology/*therapeutic use
MH  - Blood Pressure/drug effects/physiology
MH  - Body Weight/drug effects/physiology
MH  - Dietary Fats/adverse effects
MH  - Disease Models, Animal
MH  - Hypertension/*drug therapy/physiopathology
MH  - Kidney Diseases/physiopathology/*prevention & control
MH  - Male
MH  - Metabolic Syndrome/chemically induced/*physiopathology
MH  - PPAR gamma/physiology
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Telmisartan
MH  - Tetrazoles/pharmacology/*therapeutic use
MH  - Treatment Outcome
MH  - Valine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Valsartan
PMC - PMC3721747
MID - NIHMS373412
COIS- DISCLOSURES No conflicts of interest, financial or otherwise, are declared by the 
      authors.
EDAT- 2011/03/19 06:00
MHDA- 2011/10/14 06:00
PMCR- 2013/07/24
CRDT- 2011/03/19 06:00
PHST- 2011/03/19 06:00 [entrez]
PHST- 2011/03/19 06:00 [pubmed]
PHST- 2011/10/14 06:00 [medline]
PHST- 2013/07/24 00:00 [pmc-release]
AID - ajh201134 [pii]
AID - 10.1038/ajh.2011.34 [doi]
PST - ppublish
SO  - Am J Hypertens. 2011 Jul;24(7):816-21. doi: 10.1038/ajh.2011.34. Epub 2011 Mar 
      17.